Skip to main content
Fig. 2 | Stem Cell Research & Therapy

Fig. 2

From: Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases

Fig. 2

UC-MSCs immunophenotype at basal state. A Expression of mesenchymal markers (CD90, CD105, CD73), adhesion molecules (CD44, CD29, CD166, CD146), hematopoietic (CD14, CD45) and endothelial (CD31) markers. B Expression of immunogenic (HLA-ABC, HLA-DR) and co-stimulatory (CD40, CD80, CD86) markers. C Summary of markers’ expression represented as mean ± standard deviation (%) (n = 3 batches from 1 UC)

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512